ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 915

Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface

Tsuyoshi Shirai1, Hiroshi Fujii1, Tomoyuki Muto2, Yuko Shirota1, Yoko Fujita3, Tomonori Ishii1 and Hideo Harigae1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Tohoku University Graduate School of Medicine, Sendai, Japan, 3Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoantibodies, autoantigens, endothelial cells and takayasu arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: B Cell Biology and Targets in Autoimmune Disease I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Autoantibodies which recognize integral membrane proteins are generally accepted as pathogenic. However, it had been technically difficult to identify plasma membrane proteins as autoantigens by conventional methods including proteomics. Anti-endothelial cell antibodies (AECAs) are autoantibodies against cell surface molecules on the endothelium, and play important roles on promoting vascular inflammation. Most of the reported autoantigens were intracellular molecules, and their target antigens on endothelium were poorly understood. In order to identify cell-surface autoantigens, we constructed a Serological identification system for Autoantigens using a Retroviral vector and Flow cytometry (SARF).

Methods: cDNA library of human umbilical vein endothelial cells (HUVECs) were generated and inserted into the retroviral vector. Retroviruses possessing the cDNA library were generated and infected into the rat myeloma cells. Rat myeloma cells which have different HUVEC cDNA were stained with serum IgG from patients with AECA-positive collagen diseases, and AECA-positive fraction was sorted by flow cytometry. After cloning of an AECA-positive cell, cDNA inserted into each clone was identified by DNA sequencing and microarray.

Results: The identified molecules included fibronectin leucine rich transmembrane protein 2 (FLRT2), ephrin type-B receptor 2 (EphB2), and Pk antigen for systemic lupus erythematosus, and intercellular adhesion molecule-1 (ICAM-1) for rheumatoid arthritis. Expressions of these molecules on ECs were confirmed by flow cytometry and AECA IgGs bound specifically to the cells which were transfected with each of the molecules. Importantly, anti-FLRT2 antibody induced complement-dependent cytotoxicity against FLRT2 expressing cells including HUVECs. Clinical manifestations of each autoantibody-positive patient were associated with the distribution of autoantigens in different cell types, indicating that AECAs can act not only on ECs but also on other target cells. We further identified autoantigens in Takayasu arteritis, in which no definite autoantigens were reported. The autoantigens in Takayasu arteritis play important roles for the coagulation and lipid metabolism, suggesting that AECAs can directly modify vascular inflammation in Takayasu arteritis.

Conclusion: We successfully identified membrane proteins as autoantigens against AECAs by using SARF and confirmed the usefulness of SARF. Moreover, identified molecules were associated with the clinical manifestations of patients, suggesting direct contributions of AECAs for promoting pathological conditions. Using this system, it is possible to achieve a comprehensive analysis of autoantibody-mediated injury in inflammatory diseases and develop more specific interventions.


Disclosure: T. Shirai, None; H. Fujii, None; T. Muto, None; Y. Shirota, None; Y. Fujita, None; T. Ishii, Chugai, Ono, Pfizer, Tanabe Mitsubishi, Astellas, 8; H. Harigae, None.

To cite this abstract in AMA style:

Shirai T, Fujii H, Muto T, Shirota Y, Fujita Y, Ishii T, Harigae H. Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/establishment-of-a-powerful-method-to-identify-autoantigens-expressed-on-the-cell-surface/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/establishment-of-a-powerful-method-to-identify-autoantigens-expressed-on-the-cell-surface/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology